This is what analysts have to say about Sage Therapeutics, Inc. (NASDAQ:SAGE) after last week.

June 2, 2018 - By Dolores Ford

Sage Therapeutics, Inc. (NASDAQ:SAGE) LogoInvestors sentiment increased to 1.73 in Q1 2018. Its up 0.24, from 1.49 in 2017Q4. It improved, as 22 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 47 funds opened positions while 88 raised stakes. 45.19 million shares or 9.02% more from 41.45 million shares in 2017Q4 were reported.
Pnc Fin Grp Inc Inc has invested 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Farallon Cap Management Ltd Liability owns 445,000 shares. Parametric Portfolio Assocs Limited Liability Corporation accumulated 0% or 23,621 shares. Emerald Advisers Pa invested in 0.99% or 152,913 shares. Sg Americas Secs Lc has 5,233 shares for 0.01% of their portfolio. California Pub Employees Retirement System accumulated 69,665 shares. Bamco Inc New York has 0.14% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 183,263 shares. Moreover, Axa has 0.04% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 62,994 shares. Amundi Pioneer Asset Mgmt reported 103,937 shares. Lord Abbett & Commerce Limited Liability, a New Jersey-based fund reported 467,854 shares. The Tennessee-based Ftb Advisors has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Rock Springs Management Limited Partnership reported 0.34% in Sage Therapeutics, Inc. (NASDAQ:SAGE). University Of Notre Dame Du Lac invested in 0.97% or 32,278 shares. Ameritas Invest Partners has 0.03% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 3,534 shares. Jabre Prtn invested in 2,400 shares.

Since December 14, 2017, it had 0 insider purchases, and 6 selling transactions for $42.42 million activity. $10.00M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by PAUL STEVEN M on Tuesday, March 6. 7,000 shares were sold by FRATES JAMES M, worth $1.08M. IGUCHI KIMI sold $4.02 million worth of stock. Another trade for 60,000 shares valued at $9.57 million was made by Robichaud Albert on Thursday, December 14. Shares for $9.96M were sold by STARR KEVIN P.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 10 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SAGE Therapeutics had 14 analyst reports since December 7, 2017 according to SRatingsIntel. The company was maintained on Thursday, December 7 by Leerink Swann. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Canaccord Genuity on Monday, March 26. The company was maintained on Thursday, December 7 by BMO Capital Markets. The firm earned “Buy” rating on Thursday, February 22 by RBC Capital Markets. On Thursday, December 7 the stock rating was maintained by Cowen & Co with “Buy”. The stock has “Buy” rating by Chardan Capital Markets on Thursday, December 7. BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, January 31 with “Buy” rating. The firm earned “Buy” rating on Tuesday, May 22 by Chardan Capital Markets. BMO Capital Markets maintained it with “Buy” rating and $20300 target in Monday, April 23 report. The stock has “Buy” rating by Stifel Nicolaus on Thursday, December 7. Below is a list of Sage Therapeutics, Inc. (NASDAQ:SAGE) latest ratings and price target changes.

22/05/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $225.0000 Upgrade
23/04/2018 Broker: BMO Capital Markets Rating: Buy New Target: $203.0000 Maintain
26/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $210.0000 Maintain
27/02/2018 Broker: SunTrust Rating: Buy New Target: $203.0 Maintain
26/02/2018 Broker: Morgan Stanley Rating: Overweight New Target: $225 Initiates Coverage On
22/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $277.0 Maintain
31/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $203.0 Maintain
07/12/2017 Broker: Cowen & Co Rating: Buy New Target: $202.0 Maintain
07/12/2017 Broker: SunTrust Rating: Buy New Target: $178.0 Maintain
07/12/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $198.0 Maintain

The stock increased 0.45% or $0.69 during the last trading session, reaching $153.38. About 205,342 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 127.92% since June 2, 2017 and is uptrending. It has outperformed by 115.35% the S&P500.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.14 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

More news for Sage Therapeutics, Inc. (NASDAQ:SAGE) were recently published by: Streetinsider.com, which released: “SAGE Therapeutics (SAGE) Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV …” on May 30, 2018. Investingnews.com‘s article titled: “Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the …” and published on May 30, 2018 is yet another important article.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: